Cohera Medical’s Novel Sealant Picked For FDA 'Expedited Access'
This article was originally published in The Gray Sheet
Executive Summary
FDA launched its new Expedited Access Pathway in April, and Cohera Medical is now the first company to announce participation for its Sylys Surgical Sealant. Under the program, Cohera hopes to use an interim trial analysis to accelerate the product's path to market.
You may also be interested in...
Shortened ‘Cures’ Draft Retains Breakthrough Pathway, Device Reforms
But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.